Want to see SE:HUM full AI Analyst Report?
Top Page
Humana AB
(HUM)
Select Model
Select Model
Rating:71Outperform
Price Target:
kr79.00
▲(10.49% Upside)
Action:Upgraded
Date:07/23/26
The score is driven mainly by strong financial performance (notably accelerating revenue and robust free cash flow) tempered by meaningful leverage and thin net margins. Technicals add support with an uptrend above major moving averages and positive MACD, while valuation is reasonable with a mid-level P/E and moderate dividend yield.
Positive Factors
Revenue acceleration
The sharp TTM revenue acceleration indicates a meaningful improvement in demand, service volumes, or contract activity. If maintained, stronger top-line growth can improve operating leverage, support investment in care capacity, and strengthen Humana’s position across its regulated care markets.
Negative Factors
Meaningful leverage
Although leverage has improved from prior years, debt remains substantial relative to equity and operating cash flow covers only a limited share of total debt. This restricts financial flexibility and may constrain Humana’s ability to absorb earnings pressure or fund expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue acceleration
The sharp TTM revenue acceleration indicates a meaningful improvement in demand, service volumes, or contract activity. If maintained, stronger top-line growth can improve operating leverage, support investment in care capacity, and strengthen Humana’s position across its regulated care markets.
Read all positive factors
Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.43B
Dividend Yield1.85%
Average Volume (3M)153.43K
Price to Earnings (P/E)20.6
Beta (1Y)0.65
Revenue Growth-3.48%
EPS Growth-14.02%
CountrySE
Employees11,127
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)3.53
Shares Outstanding48,039,394
10 Day Avg. Volume227,474
30 Day Avg. Volume153,433
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.81
Price to Sales (P/S)0.25
P/FCF Ratio3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.32
Revenue Forecast (FY)kr10.28B
Humana AB Business Overview & Revenue Model
Company Description
Humana AB (publ), founded in 2001 and headquartered in Stockholm, Sweden, offers a wide range of individual and family care services across Sweden, Finland, Norway, and Denmark, serving both children and adults. The company's operations are divide...
How the Company Makes Money
Humana AB primarily makes money by delivering care services that are reimbursed through public-sector funding mechanisms (and, where applicable, municipal/regional contracts) and paid according to regulated or contracted rates. Key revenue streams...
Humana AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.03B | 10.01B | 10.29B | 9.65B | 9.20B | 8.19B |
| Gross Profit | 2.98B | 831.00M | 896.00M | 757.00M | 9.14B | 8.13B |
| EBITDA | 1.03B | 1.11B | 1.05B | 908.00M | 901.00M | 892.00M |
| Net Income | 174.00M | 237.00M | 144.00M | 176.00M | 210.00M | 276.00M |
Balance Sheet | ||||||
| Total Assets | 9.41B | 9.39B | 10.63B | 10.03B | 9.81B | 9.00B |
| Cash, Cash Equivalents and Short-Term Investments | 339.00M | 366.00M | 583.00M | 675.00M | 690.00M | 695.00M |
| Total Debt | 4.49B | 4.40B | 5.15B | 5.41B | 5.40B | 4.92B |
| Total Liabilities | 6.32B | 6.14B | 7.33B | 7.10B | 7.07B | 6.45B |
| Stockholders Equity | 3.09B | 3.12B | 3.16B | 2.89B | 2.74B | 2.55B |
Cash Flow | ||||||
| Free Cash Flow | 681.00M | 666.00M | 570.00M | 451.00M | 442.00M | 582.00M |
| Operating Cash Flow | 737.00M | 770.00M | 869.00M | 621.00M | 633.00M | 689.00M |
| Investing Cash Flow | -42.00M | 172.00M | -532.00M | -151.00M | -246.00M | -260.00M |
| Financing Cash Flow | -1.01B | -1.13B | -434.00M | -457.00M | -424.00M | -521.00M |
Humana AB Technical Analysis
Positive
71.50
Price Trends
67.39
Positive
61.09
Positive
53.47
Positive
Market Momentum
1.15
Negative
57.41
Neutral
76.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Positive. The current price of 71.5 is above the 20-day moving average (MA) of 69.30, above the 50-day MA of 67.39, and above the 200-day MA of 53.47, indicating a bullish trend. The MACD of 1.15 indicates Negative momentum. The RSI at 57.41 is Neutral, neither overbought nor oversold. The STOCH value of 76.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HUM.
Humana AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr20.63B | 35.18 | 10.82% | 0.87% | 0.82% | 77.45% | |
71 Outperform | kr3.43B | 20.62 | 5.55% | 1.85% | -3.48% | -14.02% | |
68 Neutral | kr12.93B | 18.53 | 15.11% | 1.50% | 13.33% | 28.61% | |
67 Neutral | kr7.34B | 18.77 | 5.03% | 3.56% | -3.08% | -10.70% | |
65 Neutral | kr17.68B | 19.11 | ― | 0.71% | -1.07% | 81.76% | |
64 Neutral | kr38.60B | 41.16 | ― | 0.85% | 5.73% | 90.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:HUM
Humana AB
72.80
31.03
74.30%
SE:MCOV.B
Medicover AB
259.50
-0.29
-0.11%
SE:ATT
Attendo AB
127.30
59.00
86.37%
SE:ALIF.B
AddLife AB
171.70
-11.10
-6.07%
SE:ARJO.B
Arjo AB
26.66
-3.64
-12.02%
SE:AMBEA
Ambea AB
177.00
49.34
38.65%
Humana AB Corporate Events
Humana Names New Head of Assistans Amid Ambea Takeover
Oct 2, 2026
Humana AB has appointed long-time executive Jenny Karlsson as acting Business Area Manager for Humana Assistans, promoting her from deputy manager to lead the personal assistance operations from November 7, 2026. The internal promotion underscores...
Court of Appeal to Review Humana Assistans Damages Claim Against Swedish State
Aug 14, 2026
Humana Assistans AB, a subsidiary of Nordic care provider Humana, has secured leave to appeal a District Court ruling that rejected its damages claim against the Swedish state. The Court of Appeal’s decision means the substantive merits of H...
Humana boosts profitability and cash flow despite muted growth in Q2 2026
Jul 17, 2026
Humana AB reported modest top-line growth for the second quarter of 2026, with net revenue up 3 percent to SEK 2,581 million, while adjusted operating profit improved by 6 percent to SEK 81 million, reflecting better profitability in Sweden and Fi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.